Bedrijfsoverzicht
Moolec Science SA is a science-based ingredient company focused on the development of ingredients for food, pet food, animal feed, and dietary supplements. The organization utilizes molecular farming technology and precision fermentation platforms to execute its operations from facilities located in the Cayman Islands and internationally. This entity operates within the healthcare sector, specifically inside the biotechnology industry, which generally implies a focus on innovative, research-driven solutions for nutritional applications. The company's current scale is defined by a market capitalization of $5.16M, while annual revenue and employee count data are not currently reported in the available financial records. These valuation figures indicate that Moolec Science SA is a small-cap entity, suggesting it is an early-stage or niche player within the broader biotechnology landscape rather than a large-scale market leader.
Financiële gezondheid
The company reports no revenue (TTM), net income (TTM), or EBITDA figures in the current financial dataset, presenting a scenario where traditional profitability metrics are unavailable for analysis. Without reported revenue and net income, it is impossible to calculate a standard profit margin, as the gap between revenue and costs cannot be quantified when revenue is absent. Similarly, the absence of free cash flow data means there is no visible evidence of the company's current financial flexibility or its ability to fund operations without external capital. Despite the lack of positive earnings, the company maintains a forward P/E ratio of -29.63, which typically signals that the market expects future earnings, though the current profit margin is effectively 0.0%. The gross margin is recorded at 0.0%, and the operating margin is also 0.0%, indicating that the company has not yet generated positive gross or operating profits in the periods measured. The profit margin is stated as 0.0%, reinforcing the current lack of realized profitability from sales. Regarding liquidity and leverage, the available data lists cash, debt, and the debt-to-equity ratio as N/A, preventing a direct comparison of total cash versus total debt or an assessment of whether the balance sheet is conservative or leveraged based on traditional metrics. Furthermore, the current ratio, return on equity, and return on assets are all listed as N/A, meaning there is no data to explain short-term liquidity positions or the effectiveness of management in generating returns on shareholder equity or total assets.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is reported at -29.63, creating a divergence that implies the market is pricing in expected future earnings that have not yet materialized in historical results. The price-to-book ratio stands at 10.17, a figure that indicates the market values the company's equity at more than ten times its book value, suggesting a significant premium over the accounting book value of its net assets. The price-to-sales ratio is listed as N/A, and the EV/EBITDA is also N/A, which means alternative valuation metrics that typically help assess value relative to sales or enterprise earnings are currently unavailable for this specific ticker. In terms of trading range, the 52-week high is $157.05 and the 52-week low is $3.08, highlighting a massive volatility range within the past year. Given that the current market price sits between these extremes, the stock is trading well below its 52-week high but above its 52-week low, reflecting the typical price discovery process for small-cap biotechnology firms. The beta value is listed as N/A, so it is not possible to quantify the stock's price volatility relative to the broader market movements using this specific metric.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison to determine if earnings are growing faster or slower than revenue. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which indicates that the company reinvests all available earnings, if any, or relies on capital raising rather than distributing income to shareholders. The 0.0% payout ratio confirms that the company is not currently distributing cash to investors, a common strategy for biotechnology firms that prioritize research and development over shareholder payouts. Overall, the growth and income profile is characterized by a lack of historical financial performance data and a current absence of dividend income, relying instead on the potential for future development of nutritional supplements through molecular farming technology.